Sphera Global Health Care and Medison were among the participants in a round that took Orchard Therapeutics' overall funding past $290m.

Gene therapy developer Lacerta Therapeutics has secured funding from Sarepta Therapeutics as part of a licensing agreement.

Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.

Eli Lilly, AbbVie, Pfizer, Johnson & Johnson and WuXi AppTec have all backed neurological disorder drug developer Magnolia Neurosciences at launch.

Online pharmacist Capsule has taken new funding, just over a year after its Virgin-backed series A round.

James Cook University has formed its first spinout, Paragen Bio, which will commercialise autoimmune disease therapies derived from a blood-sucking tropical parasite.

Roche and AstraZeneca-backed endocrine disease therapy developer Millendo will merge with publicly-listed OvaScience, raising a further $30m in the process.

Antibiotics developer Bugworks Research has been backed by Utec in its bid to commercialise a treatment for hospital superbugs.

Based on research at MD Anderson, Magnolia Neurosciences has launched with funding from corporates AbbVie, Eli Lilly, Pfizer, Johnson & Johnson and WuXi AppTec.